Tirofiban indications and usage

Revision as of 01:10, 7 February 2014 by ShiSheng (talk | contribs) (Created page with "__NOTOC__ {{Tirofiban}} {{CMG}}; {{AE}} {{SS}} ==Indications and Usage== AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Tirofiban
AGGRASTAT® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Tirofiban
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Indications and Usage

AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, orrefractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).[1]


References

  1. ↑ "AGGRASTAT (TIROFIBAN) INJECTION, SOLUTION [MEDICURE INTERNATIONAL INC]". Retrieved 6 February 2014.

Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Tirofiban_indications_and_usage&oldid=939960"